磷酸二酯酶4抑制剂在特应性皮炎治疗中的应用
本文综述了磷酸二酯酶4(PDE4)抑制剂在特应性皮炎(AD)治疗中的作用机制与临床进展。PDE4活性在AD炎症细胞中升高,促进促炎细胞因子产生;靶向PDE4可减少这些介质。局部和口服PDE4抑制剂安全性良好,其中2%克立硼罗软膏已获美国FDA批准用于2岁以上儿童和成人AD,能早期持续改善疾病严重度和瘙痒,仅见应用时烧灼或刺痛。
要点
- PDE4在AD炎症细胞中活性增加,促进促炎细胞因子和趋化因子产生。
- 2%克立硼罗软膏已获FDA批准用于2岁以上儿童和成人AD,改善瘙痒和严重度。
- 局部和口服PDE4抑制剂安全性良好,其他PDE4抑制剂正在试验中。
核心结论
- 靶向PDE4可减少AD中促炎介质的产生,局部和口服PDE4抑制剂安全性良好。
- 2%克立硼罗软膏对AD显示早期和持续的疾病严重度及瘙痒改善。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- PDE4活性在AD患者炎症细胞中增加,导致促炎细胞因子和趋化因子产生增多。
- 2%克立硼罗软膏改善疾病严重度、瘙痒和其他AD症状,应用时烧灼和/或刺痛是唯一相关不良事件。
- 其他PDE4抑制剂正在试验中,显示出有前景的疗效和安全性。
关键数值与推荐
- 2%克立硼罗软膏获美国FDA批准用于2岁以上儿童和成人AD的治疗。
临床怎么用
- 2%克立硼罗软膏可作为2岁以上儿童和成人AD的局部治疗选择。
- 需注意应用时可能出现的烧灼和/或刺痛感。
局限性
- 本文为综述,未报告系统检索策略或纳入研究的偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited their use. More targeted options with fewer systemic and cutaneous side effects are needed for treating AD. Phosphodiesterase 4 (PDE4) is involved in the regulation of proinflammatory cytokines via the degradation of cyclic adenosine monophosphate. PDE4 activity is increased in the inflammatory cells of patients with AD, leading to increased production of proinflammatory cytokines and chemokines. Targeting PDE4 reduces the production of these proinflammatory mediators in AD. Both topical and oral PDE4 inhibitors have a favorable safety profile. Crisaborole 2% ointment, a topical PDE4, is now US Food and Drug Administration-approved for children older than 2 years and adults in the treatment of AD. Crisaborole 2% ointment shows early and sustained improvement in disease severity and pruritus and other AD symptoms, with burning and/or stinging upon application as the only related adverse event. Other PDE4 inhibitors are currently in trials with promising efficacy and safety.
引用
- Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2017. PMID: 29248522. doi:10.1016/j.jaad.2017.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。